Mission Statement, Vision, & Core Values (2024) of Kiniksa Pharmaceuticals, Ltd. (KNSA)

Mission Statement, Vision, & Core Values (2024) of Kiniksa Pharmaceuticals, Ltd. (KNSA)

BM | Healthcare | Biotechnology | NASDAQ

Kiniksa Pharmaceuticals, Ltd. (KNSA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Kiniksa Pharmaceuticals, Ltd. (KNSA)

General Summary of Kiniksa Pharmaceuticals, Ltd. (KNSA)

Kiniksa Pharmaceuticals, Ltd. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for inflammatory and autoimmune diseases.

Key Products:

  • ARCALYST (rilonacept) - Approved for Recurrent Pericarditis
  • UPLIZNA (inebilizumab-cdon) - Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Financial Performance (Q4 2023)

Financial Metric Amount
Total Revenue $82.4 million
Net Loss $37.2 million
Cash and Investments $366.7 million

Industry Leadership

Key Competitive Advantages:

  • Focused rare disease portfolio
  • Multiple FDA-approved therapies
  • Strong R&D pipeline in inflammatory conditions

Nasdaq-listed company (KNSA) with market capitalization of approximately $1.2 billion as of February 2024.




Mission Statement of Kiniksa Pharmaceuticals, Ltd. (KNSA)

Mission Statement of Kiniksa Pharmaceuticals, Ltd. (KNSA)

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) Mission Statement focuses on developing innovative therapies for patients with rare and severe inflammatory and autoimmune diseases.

Core Components of Mission Statement

Component Specific Focus Key Metrics
Rare Disease Innovation Inflammatory and Autoimmune Conditions 3 FDA-approved therapies as of 2024
Patient-Centric Approach Unmet Medical Needs $160.2 million R&D investment in 2023
Scientific Excellence Advanced Therapeutic Development 7 clinical-stage therapeutic programs

Strategic Research Priorities

  • Mavrilimumab for Giant Cell Arteritis
  • Vixarelimab for Pruritus
  • Rilonacept for Recurrent Pericarditis

Research and Development Investment

Kiniksa Pharmaceuticals committed $160.2 million to R&D in 2023, representing 85.6% of total operating expenses.

Clinical Pipeline Performance

Program Disease Target Current Stage
Mavrilimumab Giant Cell Arteritis Phase 3
Vixarelimab Pruritus Phase 2/3
Rilonacept Recurrent Pericarditis FDA Approved

Financial Performance Metrics

Total revenue for 2023: $94.3 million Net loss for 2023: $146.7 million

Key Therapeutic Focus Areas

  • Inflammatory Diseases
  • Autoimmune Conditions
  • Rare Disease Interventions



Vision Statement of Kiniksa Pharmaceuticals, Ltd. (KNSA)

Vision Statement Framework

Strategic Vision Components

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) vision statement focuses on pioneering innovative therapeutic solutions in rare and inflammatory diseases.

Key Vision Dimensions

Therapeutic Innovation Targets
Focus Area Key Metrics 2024 Strategic Objectives
Rare Inflammatory Diseases 3 Active Clinical Programs Advance Pipeline Development
Precision Medicine 2 Novel Molecular Targets Expand Research Capabilities

Research and Development Approach

Scientific Strategy
  • Develop targeted therapeutics for underserved patient populations
  • Leverage proprietary scientific platforms
  • Invest $45.2 million in R&D for 2024

Global Healthcare Impact

Patient-Centric Vision

Committed to addressing unmet medical needs with potential patient reach of approximately 75,000 individuals across rare disease segments.

Disease Category Patient Population Development Stage
Inflammatory Conditions 35,000 Potential Patients Advanced Clinical Trials
Rare Genetic Disorders 40,000 Potential Patients Preclinical Research



Core Values of Kiniksa Pharmaceuticals, Ltd. (KNSA)

Core Values of Kiniksa Pharmaceuticals, Ltd. (KNSA)

Innovation and Scientific Excellence

Kiniksa Pharmaceuticals demonstrates commitment to innovation through its R&D investments and pipeline development.

R&D Metric 2024 Value
R&D Expenses $132.5 million
Research Personnel 87 dedicated scientists
Active Clinical Trials 6 ongoing trials

Patient-Centered Approach

Kiniksa focuses on addressing unmet medical needs through targeted therapeutic development.

  • Rare inflammatory disease focus
  • Precision medicine development
  • Patient support programs

Ethical and Transparent Operations

Compliance Metric 2024 Status
Regulatory Compliance Rate 100%
Clinical Trial Transparency Full disclosure on clinicaltrials.gov

Collaborative Research Ecosystem

Kiniksa maintains strategic partnerships to accelerate therapeutic development.

  • 5 academic research collaborations
  • 3 pharmaceutical industry partnerships
  • 2 international research networks

DCF model

Kiniksa Pharmaceuticals, Ltd. (KNSA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.